title: Treatment of patients with coronary artery disease with biodegradable polymer based paclitaxel-eluting Infinnium coronary stent system: results of 1-year clinical follow-up a single center experience.
abstract: OBJECTIVE
  Evaluating the efficacy of the Infinnium paclitaxel-eluting coronary stent system with the biodegradable polymer in the treatment of symptomatic coronary artery disease.
  
  
  RESULTS
  Total 153 patients were treated with native coronary artery lesion treated with Infinnium paclitaxel-eluting coronary stent system. This study was a single centre, non-randomized, retrospective study. At baseline diabetes, hypertension and smoker patients were present in 53 (35%), 112 (73%) and 80 (52%) respectively. The number of patients with unstable angina and acute MI on admission was 48 (31%) and 7 (5%) respectively. Patients with left ventricular ejection fraction less than 40% were 18 of the study population. Clinical information was collected 1, 3, 6 and 12 months after procedure. Major adverse cardiac event was defined as death, non-fatal myocardial infarction and target vessel revascularization (TVR). Cumulative MACE rates were 5 (3.3%) in first month, 6 (3.9%) in 3 months, 9 (5.9%) in 6 months and 15 (9.8%) in 1-year. At the end of 1-year follow-up period, TVR was 7.8% (12 Patients), which included 8 (5.2%) PCI and 4 (2.6%) CABG Patients. 1-year survival without MACE was 90.2 %
  
  
  CONCLUSIONS
  This study demonstrates that the Infinnium paclitaxel-eluting coronary stent system with the biodegradable polymer in the treatment of symptomatic coronary artery disease is a concurrent with current standard of treatment.
authors.affiliation: Istanbul Bilim University, Florence Nightingale Hospital, Department of Cardiology, Istanbul, Turkey. vaytekin@hotmail.com
authors.forename: Aytekin
authors.initials: A
authors.lastname: Vedat
authors.forename: Gormez
authors.initials: G
authors.lastname: Selcuk
authors.forename: Erdim
authors.initials: E
authors.lastname: Refik
authors.forename: Erdogmu
authors.initials: E
authors.lastname: Onur
authors.forename: Civan
authors.initials: C
authors.lastname: Murat
authors.forename: Catakoglu Alp
authors.initials: CA
authors.lastname: Burak
authors.forename: Gulbaran
authors.initials: G
authors.lastname: Murat
authors.forename: Demiroglu
authors.initials: D
authors.lastname: Cemsid
mesh_terms: D015906:Angioplasty, Balloon, Coronary; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D003324:Coronary Artery Disease / Q000188:drug therapy* / Q000401:mortality / Q000628:therapy; D054855:Drug-Eluting Stents; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000627:therapeutic use*; D012189:Retrospective Studies; D013318:Stroke Volume; D013997:Time Factors; D014421:Turkey; D016277:Ventricular Function, Left
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel